High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Rasha T KakatiHyunsoo KimAustin WhitmanPhilip M SpanheimerPublished in: Breast cancer research and treatment (2023)
Expression and activation of the RET receptor tyrosine kinase may be driving poor outcomes in some patients with ER + breast cancer. ER + patients above the 75th percentile may benefit from clinical trials with tyrosine kinase inhibitors.
Keyphrases
- tyrosine kinase
- estrogen receptor
- epidermal growth factor receptor
- positive breast cancer
- poor prognosis
- clinical trial
- end stage renal disease
- binding protein
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- long non coding rna
- endoplasmic reticulum
- breast cancer cells
- young adults
- genome wide
- randomized controlled trial
- adipose tissue
- open label
- insulin resistance
- study protocol
- chronic myeloid leukemia